DOJ Cannabis Enforcement Policy: Federal Guidelines and Industry Impact

Executive Summary

The Department of Justice's evolving cannabis enforcement policy represents one of the most significant areas of uncertainty for the $30 billion U.S. cannabis industry, as federal prohibition under the Controlled Substances Act remains in direct conflict with state-legal programs operating in 38 states. Despite cannabis remaining a Schedule I controlled substance under 21 U.S.C. § 812, DOJ enforcement priorities have shifted dramatically over the past two decades through a series of internal memoranda, prosecutorial discretion policies, and resource allocation decisions. The current enforcement landscape leaves operators, investors, and patients navigating a complex patchwork where state-legal businesses face potential federal prosecution, banking restrictions, and tax penalties under 26 U.S.C. § 280E, even as DOJ has signaled limited interest in pursuing compliant state-licensed operators. Recent developments in 2026 have intensified questions about the durability of current enforcement postures, particularly as rescheduling proceedings advance and political leadership changes.

The stakes extend far beyond individual prosecutions. DOJ enforcement policy directly impacts access to banking services for cannabis businesses, determines whether multi-state operators can expand across state lines, influences capital formation and institutional investment, and shapes the daily operational decisions of thousands of licensed dispensaries, cultivators, and manufacturers. For patients relying on medical cannabis programs in states like California, Ohio, and Massachusetts, enforcement uncertainty creates supply chain instability and pricing volatility. Understanding the historical evolution, current framework, and future trajectory of DOJ cannabis enforcement has become essential for anyone participating in or analyzing the legal cannabis economy.

Why DOJ Enforcement Policy Matters

Federal enforcement discretion determines whether state-legal cannabis businesses operate with practical immunity or face existential legal risk, affecting $13.2 billion in annual tax revenue across state programs and medical access for 5.8 million registered patients nationwide.

The Department of Justice wields extraordinary power over the cannabis industry through its prosecutorial discretion authority. Even though 38 states have legalized medical cannabis and 24 have authorized adult-use programs, every cultivation facility, dispensary, and manufacturing operation technically violates federal law under 21 U.S.C. § 841, which prohibits the manufacture and distribution of Schedule I controlled substances. A single shift in DOJ enforcement priorities could expose thousands of state-licensed operators to federal prosecution, asset forfeiture under 21 U.S.C. § 881, and criminal penalties including mandatory minimum sentences.

The financial implications cascade throughout the economy. Cannabis businesses generated $3.7 billion in federal tax payments in 2025 despite being denied normal business deductions under 280E. State and local governments collected $13.2 billion in cannabis tax revenue that funds schools, infrastructure, and social programs. Multi-state operators like Curaleaf, Trulieve, and Green Thumb Industries have built businesses valued in the billions, employing over 428,000 workers nationwide. A return to aggressive federal enforcement would threaten this entire economic ecosystem.

For patients, DOJ policy directly impacts medicine access. Medical cannabis programs serve patients with conditions ranging from epilepsy to chronic pain, PTSD to cancer-related symptoms. Enforcement uncertainty creates supply disruptions, forces operators to maintain excessive cash reserves rather than investing in quality control, and prevents interstate commerce that could reduce prices and improve product consistency. Veterans, elderly patients, and those in underserved communities face the greatest barriers when enforcement ambiguity drives operators out of marginal markets.

Stakeholder Impact Across Sectors

Banking institutions face enforcement risk when serving cannabis clients, as providing financial services to marijuana businesses could constitute aiding and abetting violations of 21 U.S.C. § 841 or money laundering under 18 U.S.C. § 1956. Despite FinCEN guidance issued in 2014, fewer than 800 of the nation's 4,800 federally insured banks serve cannabis clients, forcing most operators to conduct business in cash. This creates security risks, tax compliance challenges, and operational inefficiencies that cost the industry an estimated $1.2 billion annually in excess expenses.

Real estate investors and landlords face forfeiture risk under federal law when leasing property to cannabis tenants. Commercial property owners have lost buildings worth millions through civil asset forfeiture proceedings, even when tenants held valid state licenses. This enforcement threat restricts available real estate for cannabis operations and inflates lease rates in markets where landlords accept the federal risk.

Ancillary service providers—from security companies to software vendors, testing laboratories to marketing agencies—must evaluate their own federal exposure when contracting with plant-touching businesses. Professional service providers including attorneys and accountants operate under ethics rules that can conflict with serving clients engaged in federally illegal activity, creating access-to-counsel issues for cannabis operators.

Background and History: The Evolution of Federal Cannabis Enforcement

DOJ cannabis enforcement policy has undergone five distinct eras since California legalized medical marijuana in 1996, shifting from aggressive prosecution to tolerance and back based on political leadership and evolving public opinion.

The Controlled Substances Act Foundation (1970-1996)

The Controlled Substances Act, enacted as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, established the legal framework that continues to govern federal cannabis enforcement. The statute created a five-schedule classification system, placing marijuana in Schedule I alongside heroin and LSD. Schedule I classification requires three findings: high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision.

For 26 years following the CSA's enactment, federal enforcement remained straightforward: all cannabis possession, cultivation, and distribution violated federal law, and DOJ prosecuted violations without regard to state law. The Drug Enforcement Administration conducted raids, the U.S. Attorney's Offices prosecuted cases, and federal courts imposed sentences under mandatory minimum statutes enacted in 1986 that required five-year prison terms for cultivating 100 plants or possessing 100 kilograms.

The Medical Marijuana Era Begins (1996-2009)

California voters approved Proposition 215, the Compassionate Use Act, in November 1996, creating the first state-legal medical cannabis program and triggering a fundamental conflict between state and federal law. The Clinton administration DOJ initially responded with threats to prosecute physicians who recommended cannabis and to revoke DEA registrations, but backed down after the Ninth Circuit ruled in Conant v. Walters that such actions violated First Amendment protections.

The George W. Bush administration took a more aggressive enforcement stance. In 2001, the Supreme Court ruled in United States v. Oakland Cannabis Buyers' Cooperative that medical necessity provided no defense to federal marijuana charges. In 2005, the Court held in Gonzales v. Raich that Congress's Commerce Clause authority permitted federal prosecution of intrastate medical marijuana cultivation even in states where such activity was legal. These decisions established that state legalization provided no protection against federal enforcement.

DEA raids on state-legal medical marijuana dispensaries intensified between 2005 and 2009, particularly in California. Federal prosecutors in the Central District of California brought dozens of cases against dispensary operators, cultivators, and landlords. The Wo/Men's Alliance for Medical Marijuana in Santa Cruz, the Los Angeles Cannabis Resource Center, and numerous other providers faced raids and prosecutions despite operating in compliance with state law.

The Ogden and Cole Memoranda (2009-2013)

The Obama administration's first term brought a dramatic shift in enforcement priorities. On October 19, 2009, Deputy Attorney General David Ogden issued a memorandum to U.S. Attorneys titled "Investigations and Prosecutions in States Authorizing the Medical Use of Marijuana." The Ogden Memo stated that federal resources should not focus on "individuals whose actions are in clear and unambiguous compliance with existing state laws providing for the medical use of marijuana."

The memo emphasized that prosecution of "significant traffickers of illegal drugs, including marijuana" remained a core DOJ priority, but suggested that patients with serious illnesses and their caregivers acting in compliance with state law should not be priorities. The guidance created an expectation of federal tolerance that fueled rapid expansion of state medical marijuana programs and commercial dispensary models.

However, the Ogden Memo's impact proved short-lived. Between 2011 and 2013, federal prosecutors launched aggressive enforcement actions against dispensaries in California, Montana, Washington, and Colorado. U.S. Attorneys sent warning letters to landlords, threatened forfeiture actions, and brought prosecutions against operators who claimed state-law compliance. The crackdown revealed that the Ogden Memo provided no binding constraint on prosecutorial discretion.

On August 29, 2013, Deputy Attorney General James Cole issued an updated memorandum that provided more detailed guidance. The Cole Memo identified eight federal enforcement priorities: preventing distribution to minors, preventing revenue from going to criminal enterprises, preventing diversion to states where cannabis remained illegal, preventing state-authorized activity from being a cover for trafficking, preventing violence and use of firearms, preventing drugged driving, preventing cultivation on public lands, and preventing possession or use on federal property.

The Cole Memo stated that in jurisdictions with "strong and effective regulatory and enforcement systems," federal resources would generally not be used to prosecute individuals or businesses acting in compliance with state law, provided they did not implicate the eight priority areas. This guidance became the foundation for the modern state-legal cannabis industry, providing sufficient comfort for institutional capital to begin entering the sector.

The Sessions Rescission (2018)

On January 4, 2018, Attorney General Jeff Sessions issued a one-page memorandum rescinding the Cole Memo and all previous DOJ guidance on marijuana enforcement. The Sessions Memo directed U.S. Attorneys to "follow the well-established principles that govern all federal prosecution" and stated that previous guidance was "unnecessary" given prosecutors' existing discretion to weigh relevant factors in deciding whether to bring charges.

The rescission created immediate uncertainty across the cannabis industry. Stock prices for publicly traded cannabis companies dropped sharply. Investors paused capital deployment. Operators questioned expansion plans. However, the practical impact proved limited—U.S. Attorneys in states with legal cannabis programs generally declined to initiate new enforcement actions, and Sessions left office in November 2018 without presiding over a significant increase in federal prosecutions.

The Current Framework (2018-Present)

Under Attorneys General Matthew Whitaker, William Barr, Merrick Garland, and subsequent leadership, DOJ has maintained a de facto policy of limited enforcement against state-compliant cannabis operators despite the Sessions rescission remaining technically in effect. No formal guidance has replaced the Cole Memo, leaving enforcement policy to operate through informal signals, resource allocation decisions, and individual U.S. Attorney discretion.

Congressional appropriations riders have provided additional protection for medical marijuana programs. Since 2014, annual appropriations bills have included provisions prohibiting DOJ from using funds to prevent states from implementing their own medical cannabis laws. Courts have interpreted this language in United States v. McIntosh to bar prosecutions of individuals acting in strict compliance with state medical marijuana laws, though the protection does not extend to adult-use programs and expires annually unless renewed.

The Biden administration has signaled support for cannabis reform through pardons for federal simple possession offenses issued in October 2022 and directives to review marijuana's Schedule I classification. In May 2024, DEA published a notice of proposed rulemaking to reschedule cannabis to Schedule III, which would maintain federal prohibition but reduce penalties and eliminate 280E tax treatment. As of June 2026, that rescheduling process remains pending, creating additional uncertainty about future enforcement frameworks.

Key Players in DOJ Cannabis Enforcement

The Attorney General and Deputy Attorney General

The Attorney General sets overall DOJ enforcement priorities and issues formal guidance to U.S. Attorneys. The Deputy Attorney General typically authors detailed policy memoranda on specific enforcement areas. These political appointees serve at the President's pleasure and can shift enforcement posture dramatically based on administration priorities, as demonstrated by the contrast between the Cole Memo and Sessions rescission.

U.S. Attorneys and the 94 Federal Judicial Districts

U.S. Attorneys exercise substantial autonomy in deciding which cases to prosecute within their districts. Even under the Cole Memo framework, individual U.S. Attorneys in California, Montana, and other states pursued aggressive enforcement against dispensaries. Conversely, after the Sessions rescission, U.S. Attorneys in Colorado, Washington, Oregon, and other legal states declined to initiate new cannabis prosecutions. This decentralized structure means enforcement can vary dramatically by geography.

The Drug Enforcement Administration

DEA conducts investigations, executes search warrants, and makes arrests for federal drug violations. The agency maintains authority to conduct enforcement actions in any state regardless of local law. DEA also controls the rescheduling process under 21 U.S.C. § 811 and maintains the federal marijuana eradication program. DEA leadership has historically opposed cannabis legalization and maintained that marijuana meets Schedule I criteria, though the agency initiated the current rescheduling proceeding following HHS's recommendation.

The Executive Office for U.S. Attorneys

EOUSA provides guidance, training, and coordination for the 94 U.S. Attorney's Offices. The office issues policy directives on charging decisions, plea agreements, and sentencing recommendations. EOUSA's role in cannabis enforcement involves translating high-level DOJ policy into operational guidance for line prosecutors.

Congressional Oversight and Appropriations Committees

The House and Senate Judiciary Committees conduct oversight of DOJ enforcement policies. The Appropriations Committees control DOJ funding and have used spending restrictions to limit medical marijuana enforcement since 2014. These committees hold hearings, request reports, and can legislatively constrain enforcement through budget riders or substantive law changes.

Legal and Regulatory Framework

Federal cannabis enforcement operates under a complex web of criminal statutes, civil forfeiture provisions, and prosecutorial discretion doctrines that create liability exposure even for state-licensed operators.

Core Criminal Statutes

21 U.S.C. § 841 prohibits the manufacture, distribution, and possession with intent to distribute controlled substances, including marijuana. Penalties scale with quantity: 100 kilograms or 100 plants triggers a five-year mandatory minimum sentence, while 1,000 kilograms or 1,000 plants requires a ten-year mandatory minimum. These thresholds encompass most commercial cultivation operations.

21 U.S.C. § 846 criminalizes conspiracy to violate the substantive drug trafficking statutes. Conspiracy charges allow prosecutors to reach individuals involved in planning or financing cannabis operations even if they never touched the product. The statute requires only an agreement to violate federal drug law and an overt act in furtherance, making it a powerful tool for prosecuting business owners and investors.

18 U.S.C. § 1956 and § 1957 prohibit money laundering and monetary transactions in property derived from specified unlawful activity. Because cannabis sales violate § 841, proceeds from state-legal marijuana businesses constitute drug trafficking proceeds under federal law. Depositing cannabis revenue in a bank account, paying rent, or purchasing equipment with cannabis proceeds can technically constitute money laundering, exposing operators and service providers to 20-year maximum sentences.

Civil Asset Forfeiture

21 U.S.C. § 881 authorizes civil forfeiture of property used to facilitate drug trafficking or purchased with drug proceeds. DOJ can seize real property, vehicles, bank accounts, and business assets connected to cannabis operations through civil proceedings that require only a preponderance of evidence. Property owners must prove their assets were not connected to drug trafficking—a burden reversal that has enabled forfeitures even when no criminal charges are filed.

The Civil Asset Forfeiture Reform Act of 2000 imposed some procedural protections, but federal forfeiture remains a significant threat to cannabis landlords, equipment lessors, and financial institutions. High-profile cases have resulted in seizures of multimillion-dollar properties leased to state-licensed dispensaries.

Tax Code Enforcement

26 U.S.C. § 280E prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses when calculating federal income tax. Cannabis businesses can deduct cost of goods sold but not rent, salaries, marketing, or other operating expenses, resulting in effective tax rates exceeding 70% in some cases. IRS enforcement of 280E has generated billions in tax revenue while creating cash flow challenges that have forced numerous operators into bankruptcy.

Prosecutorial Discretion Doctrine

The Supreme Court established in Heckler v. Chaney that prosecutorial decisions generally are not subject to judicial review. U.S. Attorneys possess broad discretion to decide which violations to prosecute based on resource constraints, enforcement priorities, and case-specific factors. This discretion enables the tolerance policies reflected in the Cole Memo but also means such policies can be reversed without legal constraint. Courts have consistently held that DOJ guidance memoranda create no enforceable rights for potential defendants.

State-by-State Enforcement Landscape

Federal enforcement risk varies significantly across states based on program maturity, regulatory robustness, U.S. Attorney posture, and local political dynamics.

California

California operates the nation's largest cannabis market with over $5.3 billion in annual legal sales, but also faces the most complex enforcement landscape. The state's medical program dates to 1996, and adult-use sales began in 2018 under Proposition 64. However, a massive illicit market—estimated at $8 billion annually—continues to operate alongside the legal sector. U.S. Attorneys in the Central, Eastern, Northern, and Southern Districts of California have historically taken varied approaches, with the Eastern District pursuing aggressive prosecutions while the Northern District has shown more tolerance for state-compliant operators. Recent enforcement has focused on illegal grows in national forests, unlicensed operations exporting to prohibition states, and organized crime networks rather than licensed dispensaries.

Colorado

Colorado's adult-use program launched in 2014 and has operated with minimal federal interference. The U.S. Attorney's Office for the District of Colorado has consistently declined to prosecute state-licensed operators, focusing instead on black market grows and interstate trafficking. Colorado's regulatory framework—including seed-to-sale tracking, strict testing requirements, and local control provisions—aligns closely with the Cole Memo priorities, providing a model for federal tolerance. The state's $423 million in cannabis tax revenue in 2025 funds school construction, substance abuse programs, and law enforcement.

Washington

Washington's adult-use program began in 2014 alongside Colorado's. The U.S. Attorney's Office for the Western District of Washington has maintained a hands-off approach to licensed operators while prosecuting unlicensed grows and trafficking organizations. Washington's closed-loop system with no home cultivation has limited diversion concerns. The state collected $559 million in cannabis excise taxes in 2025.

Oregon

Oregon's adult-use program launched in 2015 but has faced challenges with oversupply and diversion. The state's permissive licensing system created a glut of cannabis that depressed prices and incentivized illegal exports. U.S. Attorneys in Oregon have prosecuted several cases involving Oregon-grown cannabis trafficked to prohibition states. Recent state legislative reforms have tightened licensing and tracking requirements to address federal enforcement concerns.

Massachusetts

Massachusetts began adult-use sales in 2018 with a tightly regulated program emphasizing social equity and local control. The U.S. Attorney's Office for the District of Massachusetts has not pursued cases against state-licensed operators. The state's $211 million in cannabis tax revenue in 2025 supports municipal budgets and equity programs.

Michigan

Michigan's adult-use program launched in 2019 and has grown rapidly to over $3 billion in annual sales. The U.S. Attorney's Office for the Eastern District of Michigan has focused enforcement on unlicensed operations and organized crime rather than licensed businesses. Michigan's regulatory system includes stringent testing, tracking, and security requirements.

Illinois

Illinois began adult-use sales in 2020 with a program emphasizing social equity and expungement. The state's $445 million in cannabis tax revenue in 2025 funds community reinvestment, substance abuse treatment, and public safety. Federal enforcement has focused on illegal operations rather than licensed dispensaries.

New York

New York's adult-use program launched retail sales in 2022 after years of delays. The state's regulatory framework prioritizes social equity applicants and justice-involved individuals. However, a proliferation of unlicensed storefronts has complicated enforcement. U.S. Attorneys in New York have historically taken aggressive stances on financial crimes, creating uncertainty for cannabis banking and investment despite tolerance for plant-touching operations.

Ohio

Ohio operates a medical-only program that began sales in 2019. The state's 376,000 registered patients access cannabis through 120 licensed dispensaries. Federal enforcement has been minimal, with U.S. Attorneys focusing on opioid trafficking and violent crime. Ohio voters approved adult-use legalization in November 2023, with sales expected to begin in 2024 pending regulatory implementation.

Market and Business Implications

DOJ enforcement uncertainty imposes an estimated $4.7 billion annual cost on the legal cannabis industry through banking restrictions, tax penalties, limited interstate commerce, and risk premiums that constrain capital formation.

Banking and Financial Services

Fewer than 800 banks and credit unions serve cannabis clients as of 2026, forcing most operators to conduct business primarily in cash. This creates security risks, operational inefficiencies, and compliance challenges. Armored car services charge cannabis businesses 3-5 times standard rates. Point-of-sale systems must accommodate cash-only transactions. Payroll processing becomes complex when employees cannot receive direct deposits. The lack of banking access costs the industry an estimated $1.2 billion annually in excess expenses and lost efficiency.

The SAFE Banking Act, which would protect financial institutions serving state-legal cannabis businesses from federal enforcement, has passed the House seven times but has not cleared the Senate. Until federal banking protections become law, financial institutions face potential money laundering charges under 18 U.S.C. § 1956 for serving cannabis clients, regardless of state legality.

Capital Markets and Investment

Major institutional investors—pension funds, mutual funds, insurance companies—generally cannot invest in cannabis businesses due to federal illegality and fiduciary duty concerns. This limits cannabis companies to smaller investors, family offices, and specialized cannabis funds. The capital constraint depresses valuations, increases cost of capital, and limits growth potential compared to other industries.

Cannabis companies cannot list on major U.S. stock exchanges including the New York Stock Exchange and NASDAQ due to federal prohibition. Multi-state operators trade on Canadian exchanges or over-the-counter markets, reducing liquidity and institutional participation. Uplisting to major exchanges would unlock billions in institutional capital but requires federal legalization or rescheduling.

Interstate Commerce Prohibition

Federal prohibition prevents interstate cannabis commerce, forcing each state to maintain vertically integrated supply chains. California cultivators cannot ship excess inventory to undersupplied markets in New York or Massachusetts. This inefficiency increases costs, reduces product quality and consistency, and prevents economies of scale. Economists estimate interstate commerce would reduce consumer prices by 25-40% while improving product safety through consolidation around best-in-class operators.

280E Tax Burden

The inability to deduct ordinary business expenses under 26 U.S.C. § 280E creates effective tax rates of 60-80% for cannabis retailers and manufacturers. This tax burden has forced numerous operators into bankruptcy despite generating positive EBITDA. Rescheduling to Schedule III would eliminate 280E treatment, potentially saving the industry $2 billion annually in federal taxes and enabling reinvestment in quality, safety, and expansion.

Multi-State Operator Strategy

The largest cannabis companies—Curaleaf, Trulieve, Green Thumb Industries, Verano, Cresco Labs, and others—have built multi-state footprints through acquisitions and licensing. These MSOs generate $200 million to $1.5 billion in annual revenue and employ thousands. However, federal prohibition prevents them from operating as truly national businesses. Each state requires separate cultivation, processing, and distribution infrastructure. MSOs cannot leverage purchasing power across state lines or transfer best practices through personnel moves. Federal enforcement uncertainty also complicates M&A activity, as acquirers must evaluate target companies' federal compliance risk.

What Experts Say

Legal scholars, industry analysts, and policy advocates emphasize that current DOJ enforcement policy creates an unsustainable status quo that harms businesses, patients, and government revenue while failing to achieve public health or safety objectives.

According to the Congressional Research Service, the conflict between state and federal marijuana law creates "legal uncertainty for individuals and businesses operating under state law" and "complicates the enforcement of both state and federal law." The CRS has noted that DOJ's resource constraints make comprehensive enforcement of federal marijuana prohibition impossible, effectively delegating policy to prosecutorial discretion.

The American Bar Association has called for removing marijuana from the Controlled Substances Act entirely, stating that the current framework "creates confusion, uncertainty, and lack of clarity for lawyers and the public." The ABA emphasized that attorneys face ethical dilemmas when advising cannabis clients on compliance with state law that violates federal statutes.

The National Association of Attorneys General has urged Congress to resolve the state-federal conflict through legislation, noting that state enforcement of marijuana laws becomes more difficult when federal prohibition undermines state regulatory systems. State attorneys general have emphasized that federal enforcement actions against state-licensed operators undermine state sovereignty and waste state resources invested in regulatory infrastructure.

According to researchers at the RAND Corporation, inconsistent federal enforcement creates perverse incentives that benefit illegal operators while penalizing compliant businesses. RAND analysis found that enforcement uncertainty drives some operators to remain in the illicit market where they face lower tax burdens and fewer regulatory costs, undermining the public health and safety goals of state legalization.

Industry analysts at Cowen & Company have estimated that federal legalization would increase the total addressable market for legal cannabis to $100 billion annually by 2030, compared to $45 billion under continued prohibition. The analysts noted that enforcement uncertainty depresses valuations for publicly traded cannabis companies by 30-50% compared to similarly situated businesses in legal industries.

Patient advocacy organizations including Americans for Safe Access have documented how enforcement uncertainty disrupts medical cannabis supply chains, creating access barriers for seriously ill patients. The organization has called for federal rescheduling at minimum and full legalization as the optimal policy to protect patient access.

What's Next: Future Enforcement Scenarios

DOJ cannabis enforcement policy faces four potential trajectories over the next 24 months: continued tolerance under informal discretion, formal guidance restoring Cole Memo principles, aggressive enforcement under a new administration, or obsolescence through congressional legalization.

Rescheduling Timeline and Impact

The DEA's notice of proposed rulemaking to reschedule cannabis to Schedule III under 21 U.S.C. § 811 remains pending as of June 2026. The rescheduling process includes a public comment period that closed in July 2024, administrative law judge hearings scheduled for late 2024, and final rule publication expected in 2025 or 2026. If finalized, Schedule III classification would maintain federal prohibition and criminal penalties under 21 U.S.C. § 841, but would eliminate 280E tax treatment and reduce mandatory minimum sentences.

Rescheduling would not resolve the core state-federal conflict or eliminate DOJ enforcement authority. However, it would signal reduced federal concern about cannabis harms and could influence prosecutorial discretion toward greater tolerance. The pharmaceutical industry's ability to develop FDA-approved cannabis medications would expand under Schedule III, potentially creating a parallel legal market.

Congressional Legislation Prospects

The SAFE Banking Act remains the most viable near-term federal reform, with bipartisan support and banking industry backing. However, the legislation has stalled in the Senate over disagreements about whether banking reform should be paired with broader legalization and social equity provisions. If enacted, SAFE Banking would eliminate the primary enforcement threat facing financial institutions and unlock broader access to banking services.

Comprehensive legalization bills including the Cannabis Administration and Opportunity Act have been introduced but face longer odds. These bills would deschedule cannabis, establish federal regulation, and create pathways for expungement and social equity. Passage would require unified Democratic control or significant Republican support that has not yet materialized.

2024 Election Impact

The 2024 presidential election could dramatically shift DOJ enforcement posture. A Republican administration could appoint an Attorney General committed to aggressive enforcement against state-legal cannabis, reversing the tolerance policies maintained since 2018. Conversely, continued Democratic leadership would likely preserve current enforcement restraint and potentially advance rescheduling or legislative reform.

Senate control also matters, as the Judiciary Committee oversees DOJ and controls confirmation of U.S. Attorneys and the Attorney General. A Senate majority opposed to cannabis reform could block nominees perceived as too tolerant of state-legal marijuana.

State Program Expansion

Additional states are expected to legalize adult-use cannabis through ballot initiatives and legislation in 2024-2026. Each new state program increases the political difficulty of aggressive federal enforcement while expanding the universe of businesses and patients relying on DOJ tolerance. However, rapid expansion also increases diversion risks and regulatory challenges that could trigger federal intervention.

Further Reading and Primary Sources

• Controlled Substances Act, 21 U.S.C. § 801 et seq. — https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• Cole Memorandum (August 29, 2013) — https://www.justice.gov/iso/opa/resources/3052013829132756857467.pdf
• Sessions Memorandum Rescinding Cole Memo (January 4, 2018) — https://www.justice.gov/opa/press-release/file/1022196/download
• DEA Notice of Proposed Rulemaking on Rescheduling (May 2024) — https://www.federalregister.gov/
• Congressional Research Service, "Marijuana: Medical and Retail—Selected Legal Issues" — https://crsreports.congress.gov/
• United States v. Oakland Cannabis Buyers' Cooperative, 532 U.S. 483 (2001) — https://supreme.justia.com/cases/federal/us/532/483/
• Gonzales v. Raich, 545 U.S. 1 (2005) — https://supreme.justia.com/cases/federal/us/545/1/
• United States v. McIntosh, 833 F.3d 1163 (9th Cir. 2016) — https://cdn.ca9.uscourts.gov/datastore/opinions/2016/08/16/15-10117.pdf
• FinCEN Guidance on Marijuana-Related Businesses (February 14, 2014) — https://www.fincen.gov/resources/statutes-regulations/guidance/bsa-expectations-regarding-marijuana-related-businesses
• American Bar Association Resolution 10B (August 2019) — https://www.americanbar.org/